Coldstream Capital Management Inc. Purchases 308 Shares of Bruker Co. (NASDAQ:BRKR)

Coldstream Capital Management Inc. boosted its position in Bruker Co. (NASDAQ:BRKR) by 7.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,553 shares of the medical research company’s stock after buying an additional 308 shares during the period. Coldstream Capital Management Inc.’s holdings in Bruker were worth $312,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. raised its position in shares of Bruker by 120.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 399 shares of the medical research company’s stock worth $25,000 after acquiring an additional 218 shares in the last quarter. True Wealth Design LLC grew its stake in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after purchasing an additional 510 shares during the period. UMB Bank n.a. increased its holdings in Bruker by 115.3% in the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares in the last quarter. Gordian Capital Singapore Pte Ltd acquired a new position in Bruker in the second quarter valued at approximately $52,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Bruker by 81.0% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Insider Transactions at Bruker

In other Bruker news, CEO Frank H. Laukien purchased 100,000 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the acquisition, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 28.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BRKR. Barclays lowered their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. TD Cowen decreased their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Bank of America increased their price objective on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday. Wolfe Research lowered Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Finally, Wells Fargo & Company cut their price target on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $74.70.

Bruker Stock Down 1.3 %

Shares of NASDAQ:BRKR opened at $57.73 on Monday. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of 27.75, a PEG ratio of 4.00 and a beta of 1.18. The business’s 50 day moving average is $58.83 and its 200 day moving average is $62.71. Bruker Co. has a 12-month low of $48.07 and a 12-month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). The firm had revenue of $864.40 million during the quarter, compared to the consensus estimate of $866.46 million. Bruker had a return on equity of 21.52% and a net margin of 9.41%. The business’s revenue was up 16.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.74 EPS. On average, sell-side analysts forecast that Bruker Co. will post 2.4 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Shareholders of record on Monday, December 2nd will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, December 2nd. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. Bruker’s dividend payout ratio is currently 9.62%.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.